drugset / Trial / NCT04177810
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
Phase 2
Completed
25 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
American Association for Cancer Research · collabGenzyme, a Sanofi Company · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and clinical activity of plerixafor in combination with cemiplimab in patients with metastatic pancreatic cancer.
Timeline
- Start
- 2020-11-16
- Primary completion
- 2023-03-29
- Completion
- 2023-05-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |
| Subject | Plerixafor | Small molecule | 80 ug/kg | Intravenous |